☆ Ajouter favori
Fiche traitement

Cyclophosphamide

Allogene Therapeutics Cancer, Épilepsie, Lupus, Myasthénie, Myopathies, SEP

Suivi actif Phase 1

Résumé

Cyclophosphamide est développé par Allogene Therapeutics. Le traitement est actuellement en Phase 1. Il est associé à Cancer, Épilepsie, Lupus, Myasthénie, Myopathies, SEP. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.

À vérifier

À vérifier
Phase 1
Allogene Therapeutics
United States, Canada
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
2026-09-09

Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique

Phase 1
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé

Objectif scientifique de l’étude

classification automatique vérifiable
À vérifier Confiance automatique : 0%
Contrôle de cohérence : 85/100

L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.

Transparence et qualité de la fiche

données vérifiables
ClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-09-09
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source Donnée normalisée automatiquement Interprétation algorithmique

Classification scientifique multi-axes

ne pas confondre statut et résultat
État de l’étudeStatut inconnu
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable

Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.

Indicateurs factuels

sans score subjectif
Phase enregistréePhase 1
Études associées2
Publications associées16
Statut consolidéSuivi actif

Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.

Historique factuel de la molécule

23 événement(s) daté(s)

Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.

DateÉvénementSource
2018-04-12Début de l’étudeNCT03492255Registre d’essai clinique
2021-07-02Fin de l’étude prévue / enregistréeNCT03492255Registre d’essai clinique
2026-07-10PublicationRefractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma.Cureus
2026-07-10PublicationIncidence and impact of odontogenic infection-related febrile episodes during perioperative doxorubicin-cyclophosphamide or docetaxel-cyclophosphamide chemotherapy for breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2026-07-12PublicationDermatomyositis With Necrotizing Vasculitis, Pulmonary Arterial Hypertension, and Extensive Calcinosis Following Delayed Diagnosis.Cureus
2026-07-14PublicationSalvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
2026-07-14PublicationApplication Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma.Hematological oncology
2026-07-14PublicationBreakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2026-07-14PublicationMulti-omics integration reveals that pterostilbene ameliorates cyclophosphamide-induced liver injury the gut-liver axis by inhibiting inflammation and oxidative stress.Food & function
2026-07-15PublicationAlleviation effect of Potentilla anserina polysaccharides on intestinal barrier dysfunction and its underlying mechanism.International journal of biological macromolecules
2026-07-15PublicationReal-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.British journal of haematology
2026-07-23Publication[Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia].La Revue de medecine interne
2026-07-23PublicationNonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in sickle cell disease: a narrative review of safety, engraftment, and graft-versus-host-disease outcomes in adults and high-risk populations.Bone marrow transplantation
2026-08-08Création de l’enregistrementNCT03492255Registre d’essai clinique
2026-08-13PublicationSP-3 Ameliorates Established Cyclophosphamide-Induced Liver Injury and Is Associated with PPAR-Related Transcriptional and Lipid-Metabolic Changes.International journal of molecular sciences
2026-08-13PublicationAmyloidosis and Thoracic Aortic Disease: A Scoping Review.Journal of clinical medicine
2026-08-16Création de l’enregistrementNCT07524530Registre d’essai clinique
2026-08-16PublicationA systematic assessment of the short- and long-term effects of commonly used breast cancer chemotherapeutics on the gut microbiome‒blood‒brain axis of female mice.Gut microbes
2026-08-16PublicationInvestigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.Autoimmunity
2026-08-16PublicationMulti-omics reveals the mechanism of Rehmannia glutinosa Libosch. Processed with Amomum villosum Lour. in treating blood deficiency syndrome.Journal of ethnopharmacology
2026-08-19Début de l’étudeNCT07524530Registre d’essai clinique
2026-09-09Dernière mise à jour des donnéesCyclophosphamideBiomedical Watch
2036-06-01Fin de l’étude prévue / enregistréeNCT07524530Registre d’essai clinique

Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés

2 essai(s)
NCT Titre Phase Statut administratif Pays Sponsor
NCT07524530 Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Phase 2 NOT_YET_RECRUITING United States National Cancer Institute (NCI)
NCT03492255 CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid NA TERMINATED Brazil University of Sao Paulo General Hospital

Publications liées

16 publication(s)

Publications liées

16 publication(s)
Titre PMID DOI Journal Date
A systematic assessment of the short- and long-term effects of commonly used breast cancer chemotherapeutics on the gut microbiome‒blood‒brain axis of female mice. Voir source 41964565 10.1080/19490976.2026.2655149 Gut microbes
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR. Voir source 42471019 10.1080/08916934.2026.2696588 Autoimmunity
Multi-omics reveals the mechanism of Rehmannia glutinosa Libosch. Processed with Amomum villosum Lour. in treating blood deficiency syndrome. Voir source 42437650 10.1016/j.jep.2026.122184 Journal of ethnopharmacology
SP-3 Ameliorates Established Cyclophosphamide-Induced Liver Injury and Is Associated with PPAR-Related Transcriptional and Lipid-Metabolic Changes. Voir source 42589499 10.3390/ijms27156841 International journal of molecular sciences
Amyloidosis and Thoracic Aortic Disease: A Scoping Review. Voir source 42589921 10.3390/jcm15155817 Journal of clinical medicine
[Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia]. Voir source 42486736 10.1016/j.revmed.2026.07.001 La Revue de medecine interne
Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in sickle cell disease: a narrative review of safety, engraftment, and graft-versus-host-disease outcomes in adults and high-risk populations. Voir source 42486917 10.1038/s41409-026-02982-2 Bone marrow transplantation
Alleviation effect of Potentilla anserina polysaccharides on intestinal barrier dysfunction and its underlying mechanism. Voir source 42448191 10.1016/j.ijbiomac.2026.153526 International journal of biological macromolecules
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study. Voir source 42448612 10.1111/bjh.70682 British journal of haematology
Salvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review. Voir source 42445702 10.5603/rpor.110467 Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma. Voir source 42446167 10.1002/hon.70220 Hematological oncology
Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. Voir source 42444056 10.1111/pai.70425 Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Multi-omics integration reveals that pterostilbene ameliorates cyclophosphamide-induced liver injury the gut-liver axis by inhibiting inflammation and oxidative stress. Voir source 42444162 10.1039/d6fo01629d Food & function
Dermatomyositis With Necrotizing Vasculitis, Pulmonary Arterial Hypertension, and Extensive Calcinosis Following Delayed Diagnosis. Voir source 42437258 10.7759/cureus.110687 Cureus
Refractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. Voir source 42422651 10.7759/cureus.110468 Cureus
Incidence and impact of odontogenic infection-related febrile episodes during perioperative doxorubicin-cyclophosphamide or docetaxel-cyclophosphamide chemotherapy for breast cancer. Voir source 42423976 10.1007/s00520-026-10977-4 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Sources officielles

liens de recherche

Dernière mise à jour des données : 2026-09-09

Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.